Figure 1c Figure 1d Figure 1g Figure 1f Supplementary Figure 1c - - PowerPoint PPT Presentation

figure 1c figure 1d figure 1g figure 1f supplementary
SMART_READER_LITE
LIVE PREVIEW

Figure 1c Figure 1d Figure 1g Figure 1f Supplementary Figure 1c - - PowerPoint PPT Presentation

Figure 1c Figure 1d Figure 1g Figure 1f Supplementary Figure 1c Supplementary Figure 1g Figure 5e, right panels. WT+Rap WT+Rap WT Con WT Con DDX6 ESC #2 DDX6 ESC #2 WT+HBSS WT+HBSS WT+RAP WT+RAP Actin LC3 WT Con WT Con DDX6 ESC #2


slide-1
SLIDE 1

Figure 1c Figure 1d

slide-2
SLIDE 2

Figure 1g

slide-3
SLIDE 3

Figure 1f

slide-4
SLIDE 4

Supplementary Figure 1c

slide-5
SLIDE 5

Supplementary Figure 1g

slide-6
SLIDE 6
slide-7
SLIDE 7

Figure 5e, right panels. LC3

WT+Rap WT Con DDX6 ESC #2 WT+HBSS WT+RAP

Actin

WT+Rap WT Con DDX6 ESC #2 WT+HBSS WT+RAP

SQSTM1

WT Con DDX6 ESC #2 WT+HBSS WT+RAP WT Con DDX6 ESC #2 WT+HBSS WT+RAP

Actin

slide-8
SLIDE 8

Figure 6h, right panels. SQSTM1 Actin GFP‐DDX6 Nat‐DDX6 Con Con+Rap DDX6 oe Con Con+Rap DDX6 oe Con Con+Rap DDX6 oe Con Con+Rap DDX6 oe

slide-9
SLIDE 9

Control Patient Control Patient

SQSTM1 WB Actin WB

70 100 260 140 50 37 70 100 260 140 50 37

Dcp2‐ab WB pDcp2‐ab WB

Control Patient 70 100 260 140 50 37 70 100 260 140 50 37 Control Patient

For Figure 7f

slide-10
SLIDE 10

260 140 70 50 100

Supp Fig. 7: In vitro mTor assay

Supp Fig. 7: In vitro mTor assay

Supp Fig.7:+CiAP‐phospho‐ Dcp2 Ab Supp Fig.7:+CiAP‐Dcp2 Ab Fig.4C:3XFLAG Dcp2 IP Supp.Fig.2b VAD1 Overexpression